Simpson Thacher & Bartlett and Anderson Mori & Tomotsune have represented Blackstone in its 242 billion yen ($2.3 billion) acquisition of Takeda Consumer Healthcare, which turned to Nishimura & Asahi for advice. The deal is expected to close in March 2021.

Takeda Consumer Healthcare is a subsidiary of Takeda Pharmaceutical and a leading provider of over the counter (OTC) medicines in Japan.

According to Reuters, Takeda Pharmaceutical has been selling its OTC assets worldwide as it seeks to refocus its business and reduce debt from last year’s $59 billion acquisition of Shire.

The deal marks Blackstone’s second private equity transaction in Japan’s healthcare sector, following the acquisition of AYUMI Pharmaceutical in 2019.

Simpson Thacher partners Tony King, Shahpur Kabraji and Jonathan Goldstein led on the transaction. Meanwhile, the Nishimura team was led by partners Yo Ota, Hiroko Shibata and Taeko Morita.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

STB, AMT and TMI assist on $1.7 bln Blackstone Japan deal

by Nimitt Dixit |

U.S. law firm Simpson Thacher & Bartlett and Japan’s firm Anderson Mori & Tomotsune are advising global investment giant Blackstone on its $1.74 billion (275.8 billion yen) bid to take private Japanese digital comic distributor Infocom, which has hired TMI Associates to represent it.

Deals

STB guides Stonepeak on 1st Asia-dedicated infrastructure fund

by Asian Legal Business《亚洲法律杂志》 |

U.S. law firm Simpson Thacher & Bartlett has advised New York-headquartered alternative investment firm Stonepeak on raising $3.3 billion for its Stonepeak Asia Infrastructure Fund, its first fund dedicated to Asia.

Deals

Simpson Thacher advises CVC Capital on $6.8 bln Asia fund

by Mari Iwata |

U.S. law firm Simpson Thacher & Bartlett has advised PE fund CVC Capital Partners on the establishment of its sixth Asia fund, CVC Capital Partners Asia VI, which raised $6.8 billion.